Gestational age at birth and wheezing trajectories at 3–11 years

Caroline Leps,1,2 Claire Carson,2 Maria A Quigley2

ABSTRACT
Objective Children born preterm have an increased risk of asthma in early childhood. We examined whether this persists at 7 and 11 years, and whether wheezing trajectories across childhood are associated with preterm birth.

Design Data were from the UK Millennium Cohort Study, which recruited children at 9 months, with follow-up at 3, 5, 7 and 11 years.

Outcomes Adjusted ORs (aOR) were estimated for recent wheeze and asthma medication use for children born <32, 32–33, 34–36 and 37–38 weeks’ gestation, compared with children born at full term (39–41 weeks) at 7 (n=12 198) and 11 years (n=11 690). aORs were also calculated for having ‘early-remittent’ (wheezing at ages 3 and/or 5 years but not after), ‘late’ (wheezing at ages 7 and/or 11 years but not before) or ‘persistent/relapsing’ (wheezing at ages 3 and/or 5 and 7 and/or 11 years) wheeze.

Results Birth <32 weeks, and to a lesser extent at 32–33 weeks, were associated with an increased risk of wheeze and asthma medication use at ages 7 and 11, and all three wheezing trajectories. The aOR for ‘persistent/relapsing wheeze’ at <32 weeks was 4.30 (95% CI 2.33 to 7.91) and was 2.06 (95% CI 1.16 to 2.69) at 32–33 weeks. Birth at 34–36 weeks was not associated with asthma medication use at 7 or 11, nor late wheeze, but was associated with the other wheezing trajectories. Birth at 37–38 weeks was not associated with wheeze nor asthma medication use.

Conclusions Birth <37 weeks is a risk factor for wheezing characterised as ‘early-remittent’ or ‘persistent/relapsing’ wheeze.

INTRODUCTION
Recent research has shown a gradient of adverse health outcomes across the spectrum of gestational age prior to 39 weeks’ gestation.1 2 Two systematic reviews and meta-analyses have concluded that preterm birth is associated with an increased risk of asthma.14 Asthma is a chronic inflammatory disorder of the airways, characterised by widespread airflow obstruction that is reversible either with medication or spontaneously.5 Three mechanisms have been suggested that link preterm birth and asthma. First, preterm babies are more likely to suffer damage to the lungs or have chronic lung conditions, either due to structural immaturity or as a result of treatment in early life that damaged the lungs.4 6 Second, asthma and preterm birth may have common genetic components.7 Third, some prenatal exposures which could induce preterm birth, such as smoking, could also influence the risk of asthma postnatally.8

Existing evidence regarding the impact of preterm birth on asthma as children age is inconsistent, with the apparent effect of gestational age differing depending on the number of years of follow-up.1 4 Additionally, studies either focus on the risk of asthma in young children (under 6 years) or adults (over 18 years) born preterm, but very few studies have examined the association between preterm birth and asthma in late childhood and early adolescence.7–14 An earlier paper using data from the UK Millennium Cohort Study (MCS) found that children born at <39 weeks’ gestation had an increased risk of wheeze and asthma medication use at ages 3 and 5 years.8 This present study examines whether being born <39 weeks’ gestation is a risk factor for wheeze and asthma medication use in late childhood and early adolescence (7 and 11 years), and explores the association between preterm birth and different trajectories of wheezing from the ages of 3 to 11 years.

METHODS
Millennium Cohort Study
Data were drawn from the MCS, a nationally representative longitudinal study in the UK.15 Babies born during 2000–2001 were recruited from England, Wales, Northern Ireland and Scotland using a clustered, stratified design. Clusters were by electoral wards, and a baby was eligible if alive at age 9 months, and living in one of the wards.
Oversampling of certain strata allowed good representation of the four countries, Black and Minority Ethnic populations, and disadvantaged groups. A total of 18 818 children were recruited in the first survey, when caregivers were interviewed about health and sociodemographic characteristics. Follow-up interviews were conducted when the children were 3, 5, 7 and 11 years of age.15

Assessment of gestational age
Gestational age was calculated using the mother’s recall of her gestational due date, which was previously found to have good agreement with hospital records.16 Gestational age was categorised into very preterm (<32 weeks), moderately preterm (32–33 weeks), late preterm (34–36 weeks), early term (37–38 weeks) and full term (39–41 weeks).

Assessment of asthma/wheeze
Two asthma-related outcome measures were analysed based on questions included in the ages 3–11 year surveys. First, recent wheezing was assessed by maternal interview responses to a validated question17 18: ‘Has your child ever had wheezing or whistling in the chest at any time in the past 12 months?’ Second, a variable indicating the current use of asthma medications, which was asked at ages 5–11 years, was derived using the response to: ‘Is your child taking any medicines on a regular basis prescribed by a doctor, which includes pills, syrups, liquids, inhalers, patches, creams, suppositories or injections?’ A child was recorded as taking asthma medications if they were prescribed one or more medications in the following categories (based on British National Formulary codes): bronchodilators like salbutamol and Ventolin, corticosteroids, and cromoglycate and related therapy.19 Data were not available on frequency or dose.

Inclusion criteria
Singleton children who were present at the age 7 or 11 surveys, with complete information on gestational age at 9 months, and on all asthma/wheezing questions and covariate data at 7 or 11 years were included in the analysis. Children were excluded if their gestational age was improbable given the combinations of birth weight for gestational age centiles, if their natural mother was not the main respondent at the 9-month survey, or if they were born post-term (42+ weeks’ gestation), see figure 1.8 Additionally, children were excluded if they were coded as taking asthma medication, but had also been recorded as never having asthma, defined as an implausible asthma outcome.

Analysis of asthma-related outcomes at ages 7 and 11 years
Four logistic models were constructed, one for each asthma-related outcome at ages 7 and 11 years. Certain variables were included a priori in the model: child’s age at interview, sex, ethnicity and family history of asthma (mother or father has asthma). Additional sociodemographic and pregnancy-related variables were considered as potential confounders. Sociodemographic variables included: household’s national statistics socioeconomic classification, area deprivation (index of multiple deprivation), maternal education, maternal age at delivery and lone parent family. Pregnancy-related characteristics included: smoking and alcohol use during pregnancy, duration of breast feeding, birth order and mode of delivery. For details of covariate categories, see table 1.

Each potential confounder was only included in the final model if it was significantly associated with the outcome, once adjusted for the other variables in the model (Wald test p<0.05). For details of variables in final models, see table 2.

---

**Figure 1** Flow chart of study exclusions and participation. Percentages are of the original sample at 9 months, n=18 818.
### Table 1  Characteristics of Millennium Cohort Study children included in age 11 analysis

<table>
<thead>
<tr>
<th>Age 11 analysis</th>
<th>Gestational age at birth</th>
<th>P values†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>&lt;32 weeks</td>
<td>32–33 weeks</td>
</tr>
<tr>
<td>11690</td>
<td>1106 (1.0%)</td>
<td>1106 (0.9%)</td>
</tr>
<tr>
<td>Gestational age in weeks, mean (SD)</td>
<td>39.1 (1.9)</td>
<td>28.6 (1.9)</td>
</tr>
<tr>
<td>Age at interview, mean (SD)</td>
<td>11.2 (0.3)</td>
<td>11.1 (0.3)</td>
</tr>
<tr>
<td>Female, n (%)</td>
<td>5807 (48.8)</td>
<td>54 (46.0)</td>
</tr>
</tbody>
</table>

**Ethnicity, n (%)**
- White: 9806 (85.3), 83 (79.1), 85 (87.3), 511 (85.2), 1903 (83.1), 7226 (86.0), 0.03
- Black and Minority Ethnic groups: 1884 (14.7), 25 (20.9), 21 (12.7), 107 (14.8), 424 (16.9), 1307 (14.0), 0.44

**Birth weight in grams, mean (SD)‡**
- 3347.1 (572.7), 1226.7 (399.6), 2057.3 (497.9), 2660.2 (490.4), 3166.4 (482.7), 3496.2 (463.9), <0.01

**Household’s area deprivation score, n (%)**
- Top quintile: 1897 (16.9), 19 (25.7), 13 (21.9), 103 (30.0), 355 (26.5), 1407 (26.1), <0.01
- Fourth quintile: 1688 (16.8), 20 (24.1), 22 (22.4), 76 (18.2), 343 (19.7), 1227 (20.2), 0.44
- Third quintile: 2058 (20.0), 13 (10.8), 16 (18.9), 91 (18.5), 344 (17.2), 1506 (19.8), 0.44
- Second quintile: 2595 (20.0), 21 (21.0), 23 (23.6), 121 (13.5), 415 (20.9), 1913 (16.7), 0.44
- Bottom quintile: 3452 (26.4), 33 (18.5), 32 (13.2), 210 (18.0), 697 (15.5), 2480 (17.1), 0.44

**Maternal education, n (%)§**
- Higher (university degree or equivalent): 3811 (28.5), 30 (28.8), 29 (24.2), 182 (24.9), 709 (25.8), 2861 (29.6), <0.01
- Medium (A-level or equivalent): 1711 (13.8), 10 (7.7), 11 (10.6), 76 (17.2), 348 (14.0), 1266 (14.0), 0.02
- Lower (GCSE or equivalent/overseas): 4608 (42.6), 43 (38.6), 52 (53.1), 269 (44.2), 926 (43.5), 3318 (42.1), 0.02
- No formal qualification: 1554 (15.1), 23 (24.9), 14 (15.8), 91 (18.5), 344 (16.7), 1082 (13.0), 0.02

**Maternal age at delivery (years) mean (SD)¶**
- 28.1 (6.0), 27.8 (6.0), 28.6 (6.3), 27.8 (6.0), 28.3 (6.0), 28.1 (6.0), 0.94

**Table 1** Characteristics of Millennium Cohort Study children included in age 11 analysis

**Analysis of wheezing trajectories**
MCS children who satisfied the previous inclusion criteria, but additionally were present at the age 3, 5, 7 and 11 surveys were included (n=9918). Children were classified into recognised wheezing trajectories according to their wheezing trajectory at ages 3–11: ‘no wheeze’ (no wheeze present at ages 3, 5, 7 and 11 years); ‘early-remittent wheeze’ (wheezing at 3 and/or 5 years but not thereafter); ‘late-wheeze’ (wheezing at 7 and/or 11 years)

Unweighted counts and survey-weighted proportions reported.
*Similar demographics at age 7 analysis, not included.
†From weighted test for association.
‡Ten birth weight data missing.
§Six maternal qualification data missing.
¶Twenty one type of delivery data missing.
GCSE, General Certificate of Secondary Education.
but not before); and ‘persistent/relapsing wheeze’ (wheezeing at ages 3 and/or 5 and again at 7 and/or 11 years).20–22 ORs for each wheezing trajectory by gestational age group were calculated using multinomial logistic regression with adjustment for the same covariates as the previous logistic models. Children with ‘no wheeze’ at all surveys were the comparison group. The results of the analysis for recent wheeze compared with those born at full term, they were at no increased risk of ‘late’ wheeze. There were no statistically significant associations between birth at 37–38 weeks’ gestation and wheezing in the last 12 months or current asthma medication use at age 7 or 11. While these children had approximately 1.4 times the odds of ‘early-remittent’ and ‘persistent/relapsing’ wheeze compared with those born at full term, they were at no increased risk of ‘late’ wheeze. There were no statistically significant associations between birth at 37–38 weeks’ gestation and either of the asthma-related outcomes at age 7 or 11 years, nor any of the wheezing trajectories. A comparison of the results of this analysis at ages 7 and 11, with that of a previous study that examined asthma outcomes in the MCS at ages 3 and 5, can be found in figure 2.8

DISCUSSION

Our study suggests that children born preterm (<37 weeks’ gestation) are at an increased risk of ‘early-remittent’ and ‘persistent/relapsing’ wheeze, and there is a gradient of risk observed across the gestational age groups. Children born at <32 weeks, and to a lesser extent, those born at 32–33 weeks, are also more likely to experience ‘late’ wheeze than those born at full term. The results of the analysis for recent wheeze and asthma medication use at ages 7 and 11 are concordant with the findings regarding wheezing trajectories compared with their peers born at full term, and this was only statistically significant for ‘persistent/relapsing’ wheeze (OR 2.06, 95% CI 1.16 to 2.69). There were no statistically significant associations between birth at 34–36 weeks’ gestation and wheezing in the last 12 months or current asthma medication use at age 7 or 11. While these children had approximately 1.4 times the odds of ‘early-remittent’ and ‘persistent/relapsing’ wheeze compared with those born at full term, they were at no increased risk of ‘late’ wheeze. There were no statistically significant associations between birth at 37–38 weeks’ gestation and either of the asthma-related outcomes at age 7 or 11 years, nor any of the wheezing trajectories. A comparison of the results of this analysis at ages 7 and 11, with that of a previous study that examined asthma outcomes in the MCS at ages 3 and 5, can be found in figure 2.8

RESULTS

At both the age 7 and 11 years survey, 98.1% of present children had complete information on asthma-related outcomes and covariates (n=12 198 and 11 690 at the age 7 and 11 surveys, respectively). Approximately 7.7% of children at both surveys were born <32 weeks’ gestation. Increasing prematurity was associated with decreasing birth weight (table 1). Black and Minority Ethnic group babies were over-represented in the lower gestational age groups. Gestational age was also significantly associated with sex, maternal qualifications, smoking during pregnancy, duration of breast feeding, birth order and type of delivery.

At ages 7 and 11, approximately 11% of children had recent wheeze and 5% were currently on asthma medication (table 2). Among the 9918 children with asthma-related data available at 3, 5, 7 and 11 years, 15.8% were classified as ‘early-remittent wheeze’, 6.7% as ‘late wheeze’, 11.4% as ‘persistent/relapsing wheeze’ and 65.8% as ‘no wheeze’. Children born at <32 weeks’ gestation were at an increased risk of asthma-related outcomes at ages 7 and 11: they had a threefold increased odds for current use of asthma medication and a twofold increased odds for recent wheeze at both ages (table 2). They also had three to four times the odds for all wheezing trajectories compared with their full-term peers (table 3). Children born at 32–33 weeks’ gestation also tended to be at an increased risk of both asthma-related outcomes, but these effects were not as large and were not always statistically significant. They also had an increased odds for all wheezing trajectories compared with their peers born at full term, but this was only statistically significant for ‘persistent/relapsing’ wheeze (OR 2.06, 95% CI 1.16 to 2.69). There were no statistically significant associations between birth at 34–36 weeks’ gestation and wheezing in the last 12 months or current asthma medication use at age 7 or 11. While these children had approximately 1.4 times the odds of ‘early-remittent’ and ‘persistent/relapsing’ wheeze compared with those born at full term, they were at no increased risk of ‘late’ wheeze. There were no statistically significant associations between birth at 37–38 weeks’ gestation and either of the asthma-related outcomes at age 7 or 11 years, nor any of the wheezing trajectories. A comparison of the results of this analysis at ages 7 and 11, with that of a previous study that examined asthma outcomes in the MCS at ages 3 and 5, can be found in figure 2.8

DISCUSSION

Our study suggests that children born preterm (<37 weeks’ gestation) are at an increased risk of ‘early-remittent’ and ‘persistent/relapsing’ wheeze, and there is a gradient of risk observed across the gestational age groups. Children born at <32 weeks, and to a lesser extent, those born at 32–33 weeks, are also more likely to experience ‘late’ wheeze than those born at full term. The results of the analysis for recent wheeze and asthma medication use at ages 7 and 11 are concordant with the findings regarding wheezing trajectory. Children <32 weeks and to a lesser extent those born at 32–33 weeks were at an increased risk for these outcomes. A previous analysis of the same cohort identified these groups

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Asthma outcomes by gestational age group at ages 7 and 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wheezing in the last 12 months</td>
<td>Gestational age groups</td>
</tr>
<tr>
<td>At 7 years</td>
<td>&lt;32 weeks; very preterm</td>
</tr>
<tr>
<td>n (%)</td>
<td>n=103</td>
</tr>
<tr>
<td>OR unadjusted (95% CI)</td>
<td>2.22 (1.26 to 3.90)</td>
</tr>
<tr>
<td>Fully adjusted OR (95% CI)</td>
<td>2.04 (1.12 to 3.72)</td>
</tr>
<tr>
<td>At 11 years</td>
<td>n=106</td>
</tr>
<tr>
<td>n (%)</td>
<td>n=106</td>
</tr>
<tr>
<td>OR unadjusted (95% CI)</td>
<td>1.65 (0.96 to 2.82)</td>
</tr>
<tr>
<td>Fully adjusted OR (95% CI)</td>
<td>1.64 (0.93 to 2.91)</td>
</tr>
</tbody>
</table>

Unweighted counts and survey-weighted proportions reported.

*Adjusted for child’s sex, ethnicity and age at interview; household’s national statistics socioeconomic classification, maternal age at delivery, lone parent family and alcohol use during pregnancy.

<table>
<thead>
<tr>
<th>Table 2</th>
<th>Asthma outcomes by gestational age group at ages 7 and 11</th>
</tr>
</thead>
<tbody>
<tr>
<td>Currently on asthma medication</td>
<td>At 7 years</td>
</tr>
<tr>
<td>n (%)</td>
<td>n=103</td>
</tr>
<tr>
<td>OR unadjusted (95% CI)</td>
<td>3.29 (1.45 to 7.44)</td>
</tr>
<tr>
<td>Fully adjusted OR (95% CI)</td>
<td>3.01 (1.25 to 7.28)</td>
</tr>
<tr>
<td>n (%)</td>
<td>n=106</td>
</tr>
<tr>
<td>OR unadjusted (95% CI)</td>
<td>2.75 (1.28 to 5.91)</td>
</tr>
<tr>
<td>Fully adjusted OR (95% CI)</td>
<td>2.73 (1.24 to 6.02)</td>
</tr>
</tbody>
</table>
as being at an increased risk of the same outcomes at ages 3 and 5 years.8 In contrast, children born at 34–36 weeks were not at a statistically significant increased risk of wheeze nor asthma medication use at 7 and 11, despite previously being at an increased risk of asthma at ages 3 and 5 years.8 Birth at 37–38 weeks’ gestation appears not to be associated with these adverse outcome measures at the ages of 7 and 11, or any of the wheezing trajectories.

The association between preterm birth and wheeze in this study may suggest that the children experienced damage to the lungs (either mechanical or because they were not yet fully developed), as genetic (family history of asthma) and prenatal and postnatal exposures (such as smoking and social deprivation) were considered in the regression models. Other studies have reported an increased risk of asthma after mechanical ventilation in those born preterm and low birth weight.11 24 25 While the aetiology is unclear, persistent-relapsing wheeze may point to early, and long-lasting, damage to the lung tissue resulting in wheezing throughout childhood. Early-remittent wheeze, however, may include wheezing due to higher rates of respiratory infection or more transient lung injury. Preterm babies are also at increased risk of respiratory tract infections, an effect that can persist into early childhood.26 This may explain the higher risk of wheezing in early childhood, seen in Boyle’s age 3 and 5 results,8 and in our findings that decreasing gestational age is associated with increasing risk of ‘early-remittent’ wheeze. Late wheeze, likewise, may not represent true asthma, but rather an infective episode.

This increase in ‘early-remittent’ wheeze in children born preterm may also help explain some of the conflicting published evidence: a meta-analysis comparing under 5 years with over 5 years reports that preterm birth is associated with wheezing in

### Table 3 OR for different wheezing trajectories (early-remittent wheeze, late wheeze and persistent/relapsing wheeze) by gestational age group

<table>
<thead>
<tr>
<th>Asthma trajectories</th>
<th>Gestational age groups</th>
<th>&lt;32 weeks; very preterm</th>
<th>32–33 weeks; moderate preterm</th>
<th>34–36 weeks; late preterm</th>
<th>37–38 weeks; early term</th>
<th>39–41 weeks; full term</th>
</tr>
</thead>
<tbody>
<tr>
<td>No wheeze (no wheezing at 3, 5, 7 and 11)</td>
<td></td>
<td>n=50 (41.3%)</td>
<td>n=58 (55.4%)</td>
<td>n=349 (61.0%)</td>
<td>n=1317 (66.1%)</td>
<td>n=4784 (67.4%)</td>
</tr>
<tr>
<td>Early-remittent wheeze (only wheeze at 3 and/or 5)</td>
<td></td>
<td>n=27 (25.2%)</td>
<td>n=24 (19.1%)</td>
<td>n=119 (19.4%)</td>
<td>n=324 (16.7%)</td>
<td>n=1072 (15.5%)</td>
</tr>
<tr>
<td>Relative risk ratio (95% CI)*</td>
<td>2.72 (1.49 to 4.96)</td>
<td>1.52 (0.89 to 2.60)</td>
<td>1.38 (1.10 to 1.74)</td>
<td>1.11 (0.94 to 1.29)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Late wheeze (only wheeze at 7 and/or 11)</td>
<td></td>
<td>n=13 (8.7%)</td>
<td>n=11 (7.9%)</td>
<td>n=26 (5.7%)</td>
<td>n=135 (5.6%)</td>
<td>n=481 (6.8%)</td>
</tr>
<tr>
<td>Relative risk ratio (95% CI)*</td>
<td>2.19 (1.04 to 4.62)</td>
<td>1.42 (0.71 to 2.86)</td>
<td>0.91 (0.58 to 1.42)</td>
<td>0.85 (0.66 to 1.09)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Persistent/relapsing wheeze (wheeze in early life at ages 3 and/or 5, and later in life at ages 7 and/or 11)</td>
<td></td>
<td>n=29 (24.8%)</td>
<td>n=19 (17.6%)</td>
<td>n=80 (13.9%)</td>
<td>n=239 (11.6%)</td>
<td>n=761 (10.3%)</td>
</tr>
<tr>
<td>Relative risk ratio (95% CI)*</td>
<td>4.30 (2.33 to 7.91)</td>
<td>2.06 (1.16 to 2.69)</td>
<td>1.45 (1.09 to 1.94)</td>
<td>1.15 (0.97 to 1.38)</td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

Unweighted counts and survey-weighted proportions reported.

*Adjusted for child’s sex, ethnicity and age at interview; family history of asthma, household’s national statistics socioeconomic classification, maternal age at delivery, lone parent family and alcohol use during pregnancy.
both age groups, and other studies in young children that tend to find a statistically significant association between gestation <39 weeks and asthma in children <6 years. However, another meta-analysis comparing children under and over 10 years finds that the impact of prematurity on asthma disappears with age. In addition, the latter meta-analysis included older studies, and studies with older children. This highlights the importance of considering the changing pattern of wheeze through childhood, and the need for a standard definition of paediatric wheezing trajectories.

It will be important to follow the longer term prognosis for the preterm children in the MCS. Another UK cohort study (Avon Longitudinal Study of Parents and Children)) followed 12 303 children born in the early 1990s from birth to age 16.5 years, and found birth <37 weeks to be associated with a higher risk of preschool-onset and mid-childhood-onset remitting, and continuous wheeze into mid-teens. Studies that examine cohorts and found birth children born in the early 1990s from birth to age 16.5 years, Longitudinal Study of Parents and Children)) followed 12 303 trajectories. and the need for a standard definition of paediatric wheezing trajectories.

Preterm births less than 34 weeks are relatively rare, and only comprised 2% of the MCS population at age 11. As a consequence, our analysis was limited by relatively small numbers in these groups, and thus p values should be interpreted with caution. For example, there is no statistically significant association for reported wheeze at age 11 in those <32 weeks, yet other results from this study would indicate they are still at increased risk of respiratory symptoms at this age. Additionally, our analysis is limited due to parental report of gestational age, and recent wheeze and asthma medication use. Our study shows that the condition. In the MCS, as children have access to the UK’s universal healthcare system, it is likely that asthma medication is the first study to do so. However, our study has a number of strengths. First, it is a large, nationally representative cohort providing findings that are generalisable to the UK and similar settings. Second, data were available for a large number of potential confounders. Finally, owing to the availability of longitudinal data, we were able to examine wheezing trajectories of preterm children across the spectrum of gestational age at birth; to our knowledge, this is the first study to do so.

Our findings are strengthened by the use of a validated measure of wheeze, together with parental report of asthma medication. Use of asthma medications tends to be a reflection of access to healthcare, management by clinicians and carers, and severity of the condition. In the MCS, as children have access to the UK’s universal healthcare system, it is likely that asthma medication is a meaningful measure of disease severity. Future studies should examine the outcome of asthma medications use by type and frequency.

CONCLUSION
Children born preterm (<37 weeks’ gestation) tend to be at an increased risk of both ‘early-remittent’ wheeze and ‘persistent/relapsing’ wheeze compared with their full-term peers, and our results suggest a gradient of risk across the gestational age groups. Future research should examine which factors predict the different wheezing trajectories in preterm children, which may help elucidate the underlying mechanisms. Additionally, further follow-up of the MCS and other birth cohorts will allow researchers to determine whether preterm children at risk of ‘persistent/relapsing wheeze’ from ages 3 to 11 continue to have asthma-related symptoms as they enter adulthood. Identifying modifiable risk factors for ‘persistent/relapsing’ wheeze should be a priority, in order to reduce and manage the long-term respiratory morbidity caused by preterm birth.

Contributors CL carried out all statistical analyses, helped design the statistical analysis, drafted the initial manuscript and approved the final manuscript as submitted. CC and MAQ conceptualised the research question, cleaned up the Millennium Cohort Data Set, aided in statistical method design, edited the manuscript and approved the final manuscript as submitted.

Funding CL completed this study while on a Rhodes Scholarship.

Competing interests None declared.

Ethics approval Multi-Centre Research Ethics Committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement All data are freely available from the Millennium Cohort Study.

Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s)) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES


